Publication
Corrigendum to "Cancer cell membrane-modified Soluplus® micelles for gemcitabine delivery to pancreatic cancer using a prodrug approach" [Int. J. Pharm. 662 (2024) 124529].
Miguel Pereira-Silva, Luis Diaz-Gomez, Bárbara Blanco-Fernandez, Alba Ferreirós, Francisco Veiga, Angel Concheiro, Ana Cláudia Paiva-Santos, Carmen Alvarez-Lorenzo
International journal of pharmaceuticsSep 24, 2026PMID 42785053doi:10.1016/j.ijpharm.2026.127439 Published ErratumpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.